vimarsana.com

Latest Breaking News On - Jashinj wu - Page 1 : vimarsana.com

Data Show Lebrikizumab Atopic Dermatitis Effects Maintained

Lebrikizumab shows good long-term efficacy and reasonable safety in patients with moderate to severe atopic dermatitis according to the 52-week results from the phase 3 ADvocate1 and ADvocate2 trials.

BREEZE-AD-PEDS: First Data for Baricitinib in Childhood Eczema

Sustained Response at 2 Years Reported for Deucravacitinib

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Effica

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.